This course includes:
Webinar - First 5 Minutes®: Navigating Lung Cancer Together—A Clinician’s Guide to Patient Communication and Clinical Trials:
From first diagnosis to clinical trial enrollment, panelists share lessons learned and practical tools for guiding patients through one of medicine’s most complex journeys—including special considerations for small cell lung cancer.
Module 1 - First 5 Minutes®: From Suspicion to Diagnosis in SCLC - Guiding Patients Through Urgent, Clear Conversations:
When a scan points to small cell lung cancer (SCLC), the first few minutes with a patient can shape everything that follows. Delivering a suspected SCLC diagnosis requires a careful balance of clarity, compassion, and urgency without panic: signaling that serious news is coming, naming the diagnosis plainly, and framing the rapid pace of workup as necessary rather than a sign that something has gone wrong. From there, the path forward includes selecting a biopsy site, starting staging quickly with PET imaging and brain MRI, and explaining limited- vs extensive-stage disease in everyday terms before handing off to oncology and the multidisciplinary team to plan treatment together with the patient.
Module 2 - First 5 Minutes®: Lung Cancer Treatment Strategies and Biomarkers - What Patients Need to Hear:
Once a lung cancer diagnosis is confirmed, patients want to know one thing: What happens now? Modern care often draws on a combination of surgery, radiation, chemotherapy, targeted therapy, and immunotherapy. Explaining these options in plain, calm language can set the tone for the path ahead. For patients with non-small cell lung cancer, biomarker testing can be framed as matching the right treatment to the right patient. Simple analogies can also help explain how immunotherapy and targeted therapy work. Many patients carry outdated fears about chemotherapy, making it important to explain today’s outpatient care landscape and improvements in side effect management. Using shared, team-based language can help patients and families feel supported as they move forward one step at a time.
Module 3 - First 5 Minutes®: Addressing Fears About Lung Cancer Clinical Trials, Targeted Therapies, and Chemotherapy:
When patients with lung cancer hesitate about treatment or clinical trials, the barrier is usually fear rather than a lack of information. Answering the fear first means validating concerns, dispelling common misconceptions, and reinforcing that these questions are normal and can be addressed with the oncology team. Clinical trial myths call for honest reframing: Trials are voluntary, closely monitored, and frequently offered early rather than as a last resort, and they are the reason patients with lung cancer have more options and are living longer than ever before. In small cell lung cancer, where everything moves quickly, pairing urgency with hope matters—as does sending patients to their first oncology visit prepared and not panicked, with questions written down, a support person alongside them, and records in hand.